Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage
Blood products are an essential component of the management of postpartum haemorrhage, although there is lack of evidence to guide optimal use. Prospective intervention studies, including randomized trials, are needed to clarify optimal timing and dosage. The new generation of virally inactivated bl...
Gespeichert in:
| Veröffentlicht in: | Best practice & research. Clinical obstetrics & gynaecology 2008-12, Vol.22 (6), p.1075-1088 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1088 |
|---|---|
| container_issue | 6 |
| container_start_page | 1075 |
| container_title | Best practice & research. Clinical obstetrics & gynaecology |
| container_volume | 22 |
| creator | Searle, E., MRCP Pavord, S., FRCP, FRCPath Alfirevic, Z., MD, FRCOG |
| description | Blood products are an essential component of the management of postpartum haemorrhage, although there is lack of evidence to guide optimal use. Prospective intervention studies, including randomized trials, are needed to clarify optimal timing and dosage. The new generation of virally inactivated blood products, such as fibrinogen concentrate, might further enhance our knowledge of the value of individual blood components. It seems likely that antifibrinolytic agents will receive less attention in future. However, rFVIIa promises to be a powerful tool in managing massive obstetric haemorrhage, although many questions concerning its efficacy and safety in differing clinical scenarios remain unanswered. |
| doi_str_mv | 10.1016/j.bpobgyn.2008.08.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69728946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521693408001065</els_id><sourcerecordid>69728946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-66ddf544fef3eb0f45d15504b138ca954d6861454132141028a4d9baf002498f3</originalsourceid><addsrcrecordid>eNqFkV2r1DAQhoMong_9CUqvvOs6-arpjSIH9SwcEPy6k5Amk7NZ26YmrbD_3tQtCN4IAwmZ553JvEPIMwo7CrR5edx1U-zuT-OOAajdGhQekEsqOatpy9nD9c5o3bRcXJCrnI8AnLdMPiYXVCmuuIBL8v0T2jh0YTTjXHlj55iqb_u9qczoqjgfMFVTivXB4BDzbOZgq_XRTAFzFcaSDINJp2oq2cmkeRmqP2xKB3OPT8gjb_qMT7fzmnx9_-7LzW199_HD_ubtXW0FVXPdNM55KYRHz7EDL6SjUoLoKFfWtFK4RjVUSEE5o4ICU0a4tjMegIlWeX5NXpzrlr_-XDDPegjZYt-bEeOSddO-YqoVTQHlGbQp5pzQ620ATUGvvuqj3nzVq696DQpF93xrsHQDur-qzcgCvDkDWMb8FTDpbAOOFl1IaGftYvhvi9f_VLB9GIM1_Q88YT7GJY3FQ011Zhr053W5625BQZE3kv8GFr2hgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69728946</pqid></control><display><type>article</type><title>Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Searle, E., MRCP ; Pavord, S., FRCP, FRCPath ; Alfirevic, Z., MD, FRCOG</creator><creatorcontrib>Searle, E., MRCP ; Pavord, S., FRCP, FRCPath ; Alfirevic, Z., MD, FRCOG</creatorcontrib><description>Blood products are an essential component of the management of postpartum haemorrhage, although there is lack of evidence to guide optimal use. Prospective intervention studies, including randomized trials, are needed to clarify optimal timing and dosage. The new generation of virally inactivated blood products, such as fibrinogen concentrate, might further enhance our knowledge of the value of individual blood components. It seems likely that antifibrinolytic agents will receive less attention in future. However, rFVIIa promises to be a powerful tool in managing massive obstetric haemorrhage, although many questions concerning its efficacy and safety in differing clinical scenarios remain unanswered.</description><identifier>ISSN: 1521-6934</identifier><identifier>EISSN: 1532-1932</identifier><identifier>DOI: 10.1016/j.bpobgyn.2008.08.010</identifier><identifier>PMID: 18838340</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Antifibrinolytic Agents - therapeutic use ; Blood Transfusion - methods ; Clinical Protocols ; Factor VIIa - therapeutic use ; Female ; Hemostasis - drug effects ; Hemostatics - therapeutic use ; Humans ; obstetric haemorrhage ; Obstetrics and Gynecology ; postpartum haemorrhage ; Postpartum Hemorrhage - drug therapy ; Practice Guidelines as Topic ; Pregnancy ; recombinant factor VIIa ; Recombinant Proteins - therapeutic use</subject><ispartof>Best practice & research. Clinical obstetrics & gynaecology, 2008-12, Vol.22 (6), p.1075-1088</ispartof><rights>2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-66ddf544fef3eb0f45d15504b138ca954d6861454132141028a4d9baf002498f3</citedby><cites>FETCH-LOGICAL-c418t-66ddf544fef3eb0f45d15504b138ca954d6861454132141028a4d9baf002498f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1521693408001065$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18838340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Searle, E., MRCP</creatorcontrib><creatorcontrib>Pavord, S., FRCP, FRCPath</creatorcontrib><creatorcontrib>Alfirevic, Z., MD, FRCOG</creatorcontrib><title>Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage</title><title>Best practice & research. Clinical obstetrics & gynaecology</title><addtitle>Best Pract Res Clin Obstet Gynaecol</addtitle><description>Blood products are an essential component of the management of postpartum haemorrhage, although there is lack of evidence to guide optimal use. Prospective intervention studies, including randomized trials, are needed to clarify optimal timing and dosage. The new generation of virally inactivated blood products, such as fibrinogen concentrate, might further enhance our knowledge of the value of individual blood components. It seems likely that antifibrinolytic agents will receive less attention in future. However, rFVIIa promises to be a powerful tool in managing massive obstetric haemorrhage, although many questions concerning its efficacy and safety in differing clinical scenarios remain unanswered.</description><subject>Antifibrinolytic Agents - therapeutic use</subject><subject>Blood Transfusion - methods</subject><subject>Clinical Protocols</subject><subject>Factor VIIa - therapeutic use</subject><subject>Female</subject><subject>Hemostasis - drug effects</subject><subject>Hemostatics - therapeutic use</subject><subject>Humans</subject><subject>obstetric haemorrhage</subject><subject>Obstetrics and Gynecology</subject><subject>postpartum haemorrhage</subject><subject>Postpartum Hemorrhage - drug therapy</subject><subject>Practice Guidelines as Topic</subject><subject>Pregnancy</subject><subject>recombinant factor VIIa</subject><subject>Recombinant Proteins - therapeutic use</subject><issn>1521-6934</issn><issn>1532-1932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV2r1DAQhoMong_9CUqvvOs6-arpjSIH9SwcEPy6k5Amk7NZ26YmrbD_3tQtCN4IAwmZ553JvEPIMwo7CrR5edx1U-zuT-OOAajdGhQekEsqOatpy9nD9c5o3bRcXJCrnI8AnLdMPiYXVCmuuIBL8v0T2jh0YTTjXHlj55iqb_u9qczoqjgfMFVTivXB4BDzbOZgq_XRTAFzFcaSDINJp2oq2cmkeRmqP2xKB3OPT8gjb_qMT7fzmnx9_-7LzW199_HD_ubtXW0FVXPdNM55KYRHz7EDL6SjUoLoKFfWtFK4RjVUSEE5o4ICU0a4tjMegIlWeX5NXpzrlr_-XDDPegjZYt-bEeOSddO-YqoVTQHlGbQp5pzQ620ATUGvvuqj3nzVq696DQpF93xrsHQDur-qzcgCvDkDWMb8FTDpbAOOFl1IaGftYvhvi9f_VLB9GIM1_Q88YT7GJY3FQ011Zhr053W5625BQZE3kv8GFr2hgw</recordid><startdate>20081201</startdate><enddate>20081201</enddate><creator>Searle, E., MRCP</creator><creator>Pavord, S., FRCP, FRCPath</creator><creator>Alfirevic, Z., MD, FRCOG</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081201</creationdate><title>Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage</title><author>Searle, E., MRCP ; Pavord, S., FRCP, FRCPath ; Alfirevic, Z., MD, FRCOG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-66ddf544fef3eb0f45d15504b138ca954d6861454132141028a4d9baf002498f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antifibrinolytic Agents - therapeutic use</topic><topic>Blood Transfusion - methods</topic><topic>Clinical Protocols</topic><topic>Factor VIIa - therapeutic use</topic><topic>Female</topic><topic>Hemostasis - drug effects</topic><topic>Hemostatics - therapeutic use</topic><topic>Humans</topic><topic>obstetric haemorrhage</topic><topic>Obstetrics and Gynecology</topic><topic>postpartum haemorrhage</topic><topic>Postpartum Hemorrhage - drug therapy</topic><topic>Practice Guidelines as Topic</topic><topic>Pregnancy</topic><topic>recombinant factor VIIa</topic><topic>Recombinant Proteins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Searle, E., MRCP</creatorcontrib><creatorcontrib>Pavord, S., FRCP, FRCPath</creatorcontrib><creatorcontrib>Alfirevic, Z., MD, FRCOG</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Best practice & research. Clinical obstetrics & gynaecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Searle, E., MRCP</au><au>Pavord, S., FRCP, FRCPath</au><au>Alfirevic, Z., MD, FRCOG</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage</atitle><jtitle>Best practice & research. Clinical obstetrics & gynaecology</jtitle><addtitle>Best Pract Res Clin Obstet Gynaecol</addtitle><date>2008-12-01</date><risdate>2008</risdate><volume>22</volume><issue>6</issue><spage>1075</spage><epage>1088</epage><pages>1075-1088</pages><issn>1521-6934</issn><eissn>1532-1932</eissn><abstract>Blood products are an essential component of the management of postpartum haemorrhage, although there is lack of evidence to guide optimal use. Prospective intervention studies, including randomized trials, are needed to clarify optimal timing and dosage. The new generation of virally inactivated blood products, such as fibrinogen concentrate, might further enhance our knowledge of the value of individual blood components. It seems likely that antifibrinolytic agents will receive less attention in future. However, rFVIIa promises to be a powerful tool in managing massive obstetric haemorrhage, although many questions concerning its efficacy and safety in differing clinical scenarios remain unanswered.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>18838340</pmid><doi>10.1016/j.bpobgyn.2008.08.010</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6934 |
| ispartof | Best practice & research. Clinical obstetrics & gynaecology, 2008-12, Vol.22 (6), p.1075-1088 |
| issn | 1521-6934 1532-1932 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69728946 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antifibrinolytic Agents - therapeutic use Blood Transfusion - methods Clinical Protocols Factor VIIa - therapeutic use Female Hemostasis - drug effects Hemostatics - therapeutic use Humans obstetric haemorrhage Obstetrics and Gynecology postpartum haemorrhage Postpartum Hemorrhage - drug therapy Practice Guidelines as Topic Pregnancy recombinant factor VIIa Recombinant Proteins - therapeutic use |
| title | Recombinant factor VIIa and other pro-haemostatic therapies in primary postpartum haemorrhage |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T16%3A43%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20factor%20VIIa%20and%20other%20pro-haemostatic%20therapies%20in%20primary%20postpartum%20haemorrhage&rft.jtitle=Best%20practice%20&%20research.%20Clinical%20obstetrics%20&%20gynaecology&rft.au=Searle,%20E.,%20MRCP&rft.date=2008-12-01&rft.volume=22&rft.issue=6&rft.spage=1075&rft.epage=1088&rft.pages=1075-1088&rft.issn=1521-6934&rft.eissn=1532-1932&rft_id=info:doi/10.1016/j.bpobgyn.2008.08.010&rft_dat=%3Cproquest_cross%3E69728946%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69728946&rft_id=info:pmid/18838340&rft_els_id=S1521693408001065&rfr_iscdi=true |